Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 600 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
604 clinical trials found
Clinical trials

BRAINSHUTTLE

A Phase Ib/IIa, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose, Parallel-Group Study To Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ro7126209 Following Intravenous Infusion in Patients With Prodromal or Mild to Moderate Alzheimer’s Disease (NCT04639050)

Currently recruiting

BREAKWATER

An Open-label, Multicenter, Randomized Phase 3 Study of First-line Encorafenib Plus Cetuximab With or Without Chemotherapy Versus Standard of Care Therapy with A Safety Lead-in of Encorafenib And Cetuximab Plus Chemotherapy in Participants with Metastatic BRAF V600E-Mutant Colorectal Cancer (NCT04607421)

No longer recruiting

BREATHS 

Breathing Control Training (BCT) as a Treatment for Functional Seizures (FS) – a multi-centre, assessor-blinded, randomised controlled efficacy and acceptability trial (ACTRN12622000525785)

Currently recruiting

BTM utilisation for burn scar contracture

BTM utilisation for burn scar contracture - long term outcomes (Trial Not Registered)

Currently recruiting

C0371002

Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C =2%) (BeneGene-2) (NCT03861273)

No longer recruiting

C1071005

MagnetisMM-5: An Open-Label, 3-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety Of Elranatamab (Pf-06863135) Monotherapy And Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone In Participants With Relapsed/Refractory Multiple Myeloma Who Have Received At Least 1 Prior Line Of Therapy Including Lenalidomide And A Proteasome Inhibitor (C1071005) (NCT05020236)

Currently recruiting

C1131003 Pfizer ITP

An International Phase 2, Open-Label, One-Arm, Multi-Center Study to Evaluate Safety and Efficacy of PF-06835375 in Adult Participants with Moderate to Severe Primary Immune Thrombocytopenia (NCT05070845)

Currently recruiting

CA027-002

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (NCT03400332)

No longer recruiting

CA055-026

A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) [CA055-026] (NCT05469737)

Currently recruiting

CA057-001

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (NCT05519085)

Currently recruiting

CA0711000

A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor [ARPI], in Participants with Metastatic Castration-resistant Prostate Cancer [mCRPC] - rechARge (NCT06764485)

Currently recruiting

CAAD-VT

Catheter Ablation versus Anti-arrhythmic Drugs for Ventricular Tachycardia (CAAD-VT): A Randomised Trial (ACTRN12620000045910)

Currently recruiting

CADPT07A12101

Phase I, open label, study of B-cell Maturation Antigen (BCMA)-directed CAR-T cells in adult patients with multiple myeloma (NCT04318327)

Currently recruiting

CALIPSO

Multicentre, adaptive, double blind, three arm placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery (NCT05447559)

Currently recruiting

CALM-ICU

A multicentre, cluster randomised, double cross over pragmatic clinical trial comparing the safety and efficacy of enteral olanzapine with quetiapine in critically ill patients with hyperactive delirium (CALM-ICU). (ACTRN12622001532796)

Recently completed/closed

CAMBRIA-2

CAMBRIA-2: Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant [AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader] Versus Standard Endocrine Therapy [Aromatase Inhibitor or Tamoxifen] as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (NCT05952557)

Currently recruiting

CAMERA-MRI II

Catheter Ablation versus Medical Rate Control of Atrial Fibrillation in Patients with Systolic Heart Failure and Myocardial Fibrosis - An MRI Guided Multi-Centre Randomised Controlled Trial (CAMERA-MRI II). It will build on the work of the original CAMERA-MRI Trial (ACTRN12620000502932)

Currently recruiting

CAPLA Optional Long Term Follow Up

CAPLA trial: Catheter Ablation for persistent atrial fibrillation: A Multicentre randomised trial of Pulmonary vein isolation (PVI) vs PVI with posterior Left Atrial wall isolation (PWI) (ACTRN12616001436460)

Currently recruiting

CAPRI

Concentrated Albumin infusion Prior to Rescue Infliximab (CAPRI) in steroid refractory Acute Severe Ulcerative Colitis (ASUC), a randomized clinical trial (ACTRN12619001081101p)

Currently recruiting

CARTITUDE-5

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy - CARTITUDE 5 (NCT04923893)

Currently recruiting
5 6 7 8 9